-
Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)
Not Recruiting
More
This is a Phase III clinical trial to compare the efficacy of two dosages of a new infant
rehabilitation protocol - I-ACQUIRE - to usual and customary forms of infant rehabilitation
in infants who experienced Perinatal Arterial Stroke (PAS).
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Stanford Investigators
View full details
-
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Not Recruiting
More
The purpose of this study is to evaluate whether addition of a low dose of total body
irradiation (TBI) to a standard preparation for transplant [total lymphoid irradiation (TLI)
and anti-thymocyte globulin (ATG)] conditioning will help to augment donor chimerism without
reducing tolerability of this regimen or increasing the risk of graft-vs-host disease (GVHD)
Stanford is currently not accepting patients for this trial.
For more information, please contact Sivan Yani, 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
-
Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.
Not Recruiting
More
The study will determine whether patients with functioning Human Leukocyte Antigen (HLA)
matched kidney transplants for at least one year and who want to discontinue
immunosuppressive drugs can be treated with Total Lymphoid Irradiation (TLI) and rabbit
Anti-Thymocyte Globulin (rATG) and an HLA matched donor hematopoietic progenitor cell
infusion such that their drugs are successfully withdrawn while maintaining normal renal
function.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Stanford Investigators
View full details
-
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
Not Recruiting
More
This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to
treat multiple myeloma. The study is being performed to evaluate the efficacy and side
effects of treatment. Specifically, the study is designed to reduce the risk of interstitial
pneumonitis.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Not Recruiting
More
A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease
(GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell
transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high
risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Not Recruiting
More
Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given
that the median age at diagnosis is 55-60 years and frequently present compromised skin in
these patients, which increases the risk of infection. Therefore, we propose a clinical study
with allogeneic hematopoietic stem cell transplantation (HSCT) using a unique
non-myeloablative preparative regimen, TLI/ATG, to treat advanced mycosis fungoides/Sezary
syndrome (MF/SS).
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Chin, 650-721-4183.
Lead Sponsor
Stanford Investigators
View full details
-
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
Recruiting
More
This first time in human study is intended for men and women at least 18 years of age who
have advanced lung cancer which has grown or returned after being treated. In particular, it
is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and
a tumor test positive for MAGE A10 protein expression (protein or gene). This trial is a dose
escalation trial that will evaluate 3 doses of transduced cells administered after a
lymphodepleting chemotherapy regimen using a 3+3 dose escalation design .The study will take
the subject's T cells, which are a natural type of immune cell in the blood, and send them to
a laboratory to be modified. The changed T cells used in this study will be the subject's own
T cells that have been genetically changed with the aim of attacking and destroying cancer
cells.
When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepleting
chemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. The
purpose of this study is to test the safety of genetically changed T cells and find out what
effects, if any, they have in subjects with lung cancer. The study will evaluate three
different cell dose levels in order to find out the target cell dose. Once the target cell
dose is determined, additional subjects will be enrolled to further test the safety and
effects at this cell dose.
Subjects will be seen frequently by the Study Physician right after receiving their T cells
back and up to first 6 months. After that, subjects will be seen every three months. Subjects
will be seen every 6 months by their Study Physician for the first 5 years after the T cell
infusion. If the T cells are found in the blood at five years, then the subjects will
continue to be seen once a year until the T cells are no longer found in the blood for a
maximum of 15 years. If the T cells are no longer found in the blood at 5 years, then the
subject will be contacted by the Study Physician for the next 10 years. Subjects who have a
confirmed response or clinical benefit ≥4 weeks after the first T-cell infusion and whose
tumor continues to express the appropriate antigen target may be eligible for a second
infusion. All subjects, completing or withdrawing from the Interventional Phase of the study,
will enter a 15-year long-term follow-up phase for observation of delayed adverse events. All
subjects will continue to be followed for overall survival during the long-term follow-up
phase.
Stanford Investigators
View full details
-
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
Recruiting
More
The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone
marrow Transplantation are enrolling patients into a research study to determine if donor
stem cells given after a living related one Haplotype match kidney transplantation will
change the immune system such that immunosuppressive drugs can be completely withdrawn.
Stanford Investigators
View full details
-
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Not Recruiting
More
The purpose of this trial is to develop an alternative treatment for patients with poor risk
non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem
cell transplant using the patient's own cells. This is followed with non-myeloablative
transplant using stem cells from a related or unrelated donor to try and generate an
anti-lymphoma response from the new immune system.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Not Recruiting
More
The purpose of this study is to compare relapse-free survival between participants with
FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem
cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after
the time of engraftment for a two year period.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Not Recruiting
More
The primary objective of this protocol is to provide expanded access to tabelecleucel to
participants with Epstein-Barr virus-associated diseases and malignancies for whom there are
no other appropriate therapeutic options, and who are not eligible to enroll in clinical
studies designed to support the development and registration of tabelecleucel.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Not Recruiting
More
Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to
decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish
mixed chimerism using low dose total body irradiation along with immunosuppression using
cyclosporine and mycophenolate mofetil; suppress graft-vs-host and host-vs-graft reactions to
allow a mixed chimeric state to be established, encourage tolerance and prevent graft-vs-host
disease (GvHD) during the mixed chimerism period and use donor lymphocyte infusions to
convert the patient to a full chimera while developing a graft-vs-tumor effect.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
Not Recruiting
More
To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects
with newly diagnosed moderate to severe cGVHD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
Not Recruiting
More
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will
increase the overall response rate, enable a more rapid and effective steroid taper.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation
Recruiting
More
This research study is to determine if donor blood stem cells given after living, related,
HLA antigen (Ag) haplotype match or living, unrelated donor kidney transplantation. Minimal
HLA antigen matching will include matching of 2 HLA antigens that can be either HLA A, B, and
/or DR. This research will change the immune system such that immunosuppressive drugs can be
completely withdrawn or reduced to minimal dose without kidney rejection.
Stanford Investigators
View full details
-
Evaluation of the Duration of Therapy for Thrombosis in Children
Not Recruiting
More
The Kids-DOTT trial is a randomized controlled clinical trial whose primary objective is to
evaluate non-inferiority of shortened-duration (6 weeks) versus conventional-duration (3
months) anticoagulation in children with first-episode acute venous thrombosis. The first
stage of the trial has consisted of a pilot/feasibility component, which then continues as
the definitively-powered trial.
Stanford is currently not accepting patients for this trial.
For more information, please contact Clara Lo, 650-723-5535.
Stanford Investigators
View full details
-
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Not Recruiting
More
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in
patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow
failure disorder.
PURPOSE: This randomized phase I trial is studying how well cyclosporine eye drops work in
preventing graft-versus-host disease of the eye in patients who have undergone donor stem
cell transplant for hematologic cancer or bone marrow failure disorder.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 6507212372.
Stanford Investigators
View full details
-
Axicabtagene Ciloleucel Expanded Access Study
Not Recruiting
More
A multicenter, open-label expanded access protocol for the treatment of subjects with
relapsed/refractory large B-cell lymphoma.
Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of
the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968
Stanford is currently not accepting patients for this trial.
For more information, please contact Julianna Craig, .
Stanford Investigators
View full details
-
CIBMTR Research Database
Recruiting
More
The primary purpose of the Research Database is to have a comprehensive source of
observational data that can be used to study HSC transplantation and cellular therapies.
A secondary purpose of the Research Database is to have a comprehensive source of data to
study marrow toxic injuries.
Objectives:
To learn more about what makes stem cell transplants and cellular therapies work well such
as:
- Determine how well recipients recover from their transplants or cellular therapy;
- Determine how recovery after a transplant or cellular therapy can be improved;
- Determine how a donor's or recipient's genetics impact recipient recovery after a
transplant or cellular therapy;
- Determine how access to transplant or cellular therapy for different groups of patients
can be improved;
- Determine how well donors recover from the collection procedures.
Stanford Investigators
View full details
-
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Not Recruiting
More
This research study is studying a drug called obinutuzumab as a means of preventing chronic
Graft vs. Host Disease (cGVHD).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Not Recruiting
More
This study is designed as a combined Phase II/III, randomized, open label, multicenter,
prospective comparative study of sirolimus plus prednisone versus
sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD. Patients
will be stratified by transplant center and will be randomized to an experimental arm of one
of the two pre-specified experimental arms (sirolimus + prednisone or the comparator arm of
sirolimus + calcineurin inhibitor + prednisone) in a 1:1 ratio.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Not Recruiting
More
Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD.
Defibrotide is no longer available though the Emergency Use IND mechanism (also known as
compassionate use, or single patient named use). This protocol is the only mechanism by which
Defibrotide can be made available to patients in the U.S.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
Not Recruiting
More
This phase I trial studies the side effects and best dose of donor regulatory T cells in
treating patients with graft-versus-host disease affecting the liver or gastrointestinal
organs (visceral) within 100 days (acute) after undergoing a stem cell transplant.
Graft-versus-host disease occurs when donor immune cells infused in a stem cell transplant
attack the gut, skin, liver, or other organ systems of the patient. Regulatory T cells are a
type of immune cell that may be able to reduce the attack of the donor's immune cells on the
patient's normal cells and help treat graft-vs-host disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 650-721-2372.
Stanford Investigators
View full details
-
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Not Recruiting
More
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus
maintenance therapy versus the strategy of single autologous transplant plus consolidation
therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy
or single autologous transplant plus maintenance therapy as part of upfront treatment of
multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in
all arms.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
Not Recruiting
More
To test a new way to approach hematopoietic stem cell transplantation for Relapsed or
Resistant Non-Hodgkin's Lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Autologous Stem Cell Rescue for Primary Amyloidosis
Not Recruiting
More
To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for
amyloidosis.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Not Recruiting
More
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate
the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC)
compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following
autologous stem cell transplant (ASCT).
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Robeson, 6507251647.
Stanford Investigators
View full details
-
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Not Recruiting
More
This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood
stem cell (PBSC) rescue for Hodgkin's Disease
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
Not Recruiting
More
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and
whether their cGVHD responds to imatinib mesylate.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 6507212372.
Stanford Investigators
View full details
-
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Not Recruiting
More
This phase 1 trial studies the side effects and the best dose of donor CD8+ memory T-cells in
treating patients with hematolymphoid malignancies. Giving low dose of chemotherapy before a
donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may
also stop the patient's immune system from rejecting the donor's stem cells. The donated stem
cells may replace the patient's immune cells and help destroy any remaining cancer cells
(graft-versus-cancer effects). Giving an infusion of the donor's T cells (donor lymphocyte
infusion) after the transplant may help increase this effect
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Not Recruiting
More
This randomized phase III trial studies how well standard-dose combination chemotherapy works
compared to high-dose combination chemotherapy and stem cell transplant in treating patients
with germ cell tumors that have returned after a period of improvement or did not respond to
treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin,
carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by
stopping them from dividing or killing them. Giving colony-stimulating factors, such as
filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the
bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to
prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the
patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not
yet known whether high-dose combination chemotherapy and stem cell transplant are more
effective than standard-dose combination chemotherapy in treating patients with refractory or
relapsed germ cell tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Not Recruiting
More
To determine if rituximab administered after allogeneic transplantation decreases the
incidence of chronic graft-vs-host disease (cGvHD)
Stanford is currently not accepting patients for this trial.
For more information, please contact Kate Tierney, 6507257063.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Not Recruiting
More
The purpose of this study is to determine if double autologous then allogeneic hematopoietic
cell transplant may offer an improved treatment option for patients with relapsed diffuse
large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional
transplantation regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Not Recruiting
More
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant
approach for patients with advanced stage multiple myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Haploid Allogeneic Transplant Using the CliniMACS System
Not Recruiting
More
To assess the proportion of patients with donor neutrophil engraftment within 30 days of
allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after
transplantation.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Not Recruiting
More
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25
mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2)
evaluate serum and endothelial markers of veno-occlusive disease (VOD) through the analysis
of blood samples.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
Not Recruiting
More
Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell
transplant will receive 6 vaccinations of donor derived dendritic cells combined with
specific protein produced by multiple myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
Not Recruiting
More
To measure how frequently and to what degree a complication of transplant cell acute graft
versus host disease (GvHD) occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Not Recruiting
More
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab
combination regimens.
The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as
measured by complete response rate in participants with refractory diffuse large B-cell
lymphoma (DLBCL).
Participants who received an infusion of KTE-C19 will complete the remainder of the 15 year
follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Not Recruiting
More
This phase I/II trial is studying the side effects and best way to give nilotinib when given
alone or sequentially after imatinib mesylate after donor stem cell transplant in treating
patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and
imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
Allogeneic Transplantation From Related Haploidentical Donors
Not Recruiting
More
The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+
selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative
regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Recruiting
More
This phase II trial studies how well ibrutinib works in treating patients after a donor stem
cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Stanford Investigators
View full details
-
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Not Recruiting
More
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves
the clinical outcome compared with standard of care second-line therapy in patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Not Recruiting
More
For patients with hematologic malignancies undergoing allogeneic myeloablative (MA) HCT with
a T cell depleted graft, the infusion of naturally occurring regulatory T cells with
conventional T cells (T cell add back) in pre-defined doses and ratios will reduce the
incidence of acute graft vs host disease while augmenting the graft vs leukemia effect and
improving immune reconstitution.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Not Recruiting
More
For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using
cells from a healthy donor represents potentially curative treatment. In these individuals,
cure is possible because transplantation of healthy donor immune cells can fight the lymphoma
in the patient. The goal of this work is to test a strategy that activates the healthy donor
immune cells so that they more effectively fight lymphoma and can result in an increased cure
rate for these patients. Our group has previously studied CpG, an immune activating
medication, in patients with lymphoma and demonstrated modest anti-tumor responses. We now
have a more potent form of CpG which we intend to test to see if it will better activate the
donor immune cells and result in shrinkage of tumor throughout the entire body, not just at
the injected site.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Double Cord Versus Haploidentical (BMT CTN 1101)
Not Recruiting
More
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or
lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar
tissue type can be used for HCT. This study will compare the effectiveness of two new types
of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow
donated from family members with only partially matched bone marrow; and, one that uses two
partially matched cord blood units.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Not Recruiting
More
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to
evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients
undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.
The study will be separated into two parts; a dose escalation phase to assess safety,
followed by a large expansion phase to further evaluate the pharmacologic effects of either a
Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of
RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include
higher risk patients and limit the unrelated donor transplants. After safety is established
in part 1 of the study, the second portion of the study will expand the enrollment criteria
and allow transplantation by either related or unrelated donors.
This study will endeavor to identify the dose range at which RGI-2001 has an acceptable
safety profile, at which biologic activity is observed, and to guide possible dose levels to
utilize in later phase studies based on biological activity.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Not Recruiting
More
Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a
treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the
course of this study, it will be evaluated whether a particular type of blood cell, called a
cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation.
CIK cells are present in small quantities in the bloodstream but their numbers can be
expanded after a brief period of nurturing in a laboratory.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
Not Recruiting
More
This study is designed as a multicenter trial, with biological assignment to one of two study
arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation
(RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Not Recruiting
More
Acute Graft-versus-Host-Disease (GVHD) is an important cause of morbidity and mortality after
allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to determine if
any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free
survival at one year after transplant compared to the current standard prophylaxis regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Bone Marrow Grafting for Leukemia and Lymphoma
Recruiting
More
The purpose of this study is to obtain tissue samples for ongoing studies regarding
transplant outcomes and complications.
Lead Sponsor
Stanford Investigators
View full details
-
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Not Recruiting
More
This phase II trial studies donor atorvastatin treatment for the prevention of severe acute
graft-versus-host disease (GVHD) in patients undergoing myeloablative peripheral blood stem
cell (PBSC) transplantation. Giving chemotherapy and total-body irradiation (TBI) before a
donor PBSC transplant helps stop the growth of cancer cells. It may also prevent the
patient's immune system reject the donor's stem cells. When the healthy stem cells from a
donor are infused into the patient they may help the patient's bone marrow make stem cells,
red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a
donor can make an immune response against the body's normal cells. Giving atorvastatin to the
donor before transplant may prevent this from happening.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leah Galvez, 650-725-7951.
Stanford Investigators
View full details
-
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD
Not Recruiting
More
Chronic graft versus host disease (cGVHD) is a common complication of bone marrow or
hematopoietic cell transplant from another person (allogeneic transplant). This study will
determine if subjects with steroid dependent/refractory cGVHD can tolerate infusion of donor
regulatory T cells and whether their cGVHD responds to the infusion.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 650-721-2372.
Stanford Investigators
View full details
-
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
Not Recruiting
More
The study is designed as a phase III, randomized, open label, multicenter, prospective,
comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as
graft-versus-host disease (GVHD) prophylaxis after human leukocyte antigen (HLA)-matched,
related, peripheral blood stem cell transplantation in individuals with hematologic cancer.
Participants will be stratified by transplant center and will be randomly assigned to the
sirolimus/tacrolimus or tacrolimus/methotrexate arms at a 1:1 ratio.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Not Recruiting
More
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work
as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant
in treating patients with leukemia or lymphoma. Giving total lymphoid irradiation and
anti-thymocyte globulin before a donor hematopoietic cell transplant helps stop the growth of
cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells.
When the healthy stem cells from a donor are infused into the patient they may help the
patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Sometimes the transplanted cells from a donor can make an immune response against the body's
normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate
mofetil after the transplant may stop this from happening. Once the donated stem cells begin
working, the patient's immune system may see the remaining cancer cells as not belonging in
the patient's body and destroy them. Giving an infusion of the donor's white blood cells,
such as CD8+ memory T-cells, may boost this effect and may be an effective treatment to kill
any cancer cells that may be left in the body (consolidative therapy).
Stanford is currently not accepting patients for this trial.
For more information, please contact Leah Galvez, 650-725-7951.
Stanford Investigators
View full details
-
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
Not Recruiting
More
To study the effectiveness of an immunosuppressive drug sirolimus, in the treatment of
chronic graft versus host disease in combination with prednisone.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
Not Recruiting
More
The study is designed as a Phase III, randomized, open label, multicenter, prospective,
comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood
stem cells (PBSC) versus marrow from unrelated donors for transplantation in patients with
hematologic malignancies. Recipients will be stratified by transplant center and disease risk
and will be randomized to either the PBSC or marrow arm in a 1:1 ratio.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kate Tierney, 6507257063.
Stanford Investigators
View full details
-
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
Not Recruiting
More
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of
NHL.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
Not Recruiting
More
The purpose of the study is to evaluate the overall and disease free survival of recipients
who have received G-CSF mobilized stem cells from HLA matched sibling donors.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Not Recruiting
More
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the
reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Not Recruiting
More
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched
related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
Not Recruiting
More
The purpose of the study is to determine the toxicity and feasibility of non-myeloablative
allogeneic hematopoietic cell transplants for multiple myeloma from unrelated donors.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
Not Recruiting
More
The purpose of this study was to assess the efficacy of ruxolitinib in combination with
corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host
disease (GVHD).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Not Recruiting
More
The purpose of the study is to conduct a phase I study of adoptive immunotherapy with
autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate
in autologous stem cell transplant patients with high-risk hematologic malignancies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sherry Moore, 6507257951.
Stanford Investigators
View full details
-
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Not Recruiting
More
Acute myeloid leukemia (AML) is a cancer of the bone marrow that mostly affects older adults.
Even with the best chemotherapy, two-year disease-free survival is achieved in a minority of
patients. Bone marrow transplantation from a sibling donor may improve cure rates; however,
patients over 50 years of age have a high risk of complications and therefore generally are
excluded from this treatment option. Recently our group developed a transplantation strategy
for older cancer patients that protects against transplant-associated complications, yet does
not interfere with the ability of the transplanted donor cells to destroy cancer cells. With
this new method, we can now safely evaluate transplantation as a curative therapy for AML
patients over the age of 50. We have assembled clinical and scientific researchers throughout
the state of California to study and compare bone marrow transplantation using our new
approach with the best standard of care chemotherapy in AML patients over the age of 50. The
results of this study have the potential to establish a new treatment standard that will
improve survival of older AML patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 650-725-1647.
Lead Sponsor
Stanford Investigators
View full details
-
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Not Recruiting
More
The purpose of this research study is to investigate whether or not maribavir is safe and
effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who
have had a stem cell transplant.
Stanford is currently not accepting patients for this trial.
For more information, please contact Janice Brown, 6507230822.
Stanford Investigators
View full details
-
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Not Recruiting
More
This phase II trial studies how well giving fluticasone propionate, azithromycin, and
montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans
who previously underwent stem cell transplant. FAM may be an effective treatment for
bronchiolitis obliterans
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Transplantation for Patients With Chronic Lymphocytic Leukemia
Not Recruiting
More
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell
transplantation for the treatment of chronic lymphocytic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Allo BMT in Advanced Leukemia or High Grade Lymphoma
Not Recruiting
More
To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the
treatment of advanced leukemia or lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
Not Recruiting
More
To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly
patients with advanced stage MDS and MPD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Not Recruiting
More
The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating
the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as
initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD
free survival at Day 56 post randomization.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
